The Effect of Oral Glucosamine Supplementation on Young Adults Experiencing Mild, Undiagnosed Knee Pain.

In young adults experiencing mild, undiagnosed knee pain, is oral Glucosamine sulphate more effective than a placebo in reducing joint pain and improving function?

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000168954

Enrollment

Registered

2011-02-11

Start date

2011-05-13

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Glucosamine sulphate is a supplement that is marketed as a joint builder. Potential benefits include: restoration in joint function, an increase in joint flexibility, and alleviation of joint pain. Previous investigations into glucosamine sulphate have found it to have a positive effect on cartilage regeneration within the knee joint, along with a lower incidence of adverse reactions when compared to other over the counter medications used to treat knee pain, such as non steroidal anti-inflammatory drugs. This study will aim to determine whether oral supplementation with a product containing GS is effective in reducing pain and improving physical function of the knee joint in young people suffering from “regular (once a week), mild, undiagnosed knee pain”. Male and female participants aged between 18-35 years of age will be recruited and randomly allocated into one of two groups: 1. Glucosamine sulphate containing product 2. Placebo (Maltodextrin, which is has no published effects on joint function) The trial will last for 8 weeks, and a number of measures will be employed during this time to assess the effects of the glucosamine sulphate supplementation e.g. a daily log of medication usage and physical activity.

Interventions

Oral administration of a glucosamine sulphate containing product (Pharmafoods Chondrotabs), containing: Glucosamine sulphate-potassium chloride (664mg), Chondroitin sulphate (400mg), and Dimethyl sulphone (400mg) The placebo group will receive tablets containing maltodextrin Participants in both groups will take one tablet, three times a day, over an 8 week period.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

- people experiencing regular, mild, undiagnosed knee pain - knee pain must be experienced at least once a week

Exclusion criteria

- pregnancy - breast feeding mothers - previous diagnosis of a meniscal (knee cartilage) or ligamentous knee injury - previous history of knee surgery, -allergies to seafood, glucosamine, shark cartilage, chondroitin or Dimethyl sulphone - allergies to maltodextrin wheat, corn, potatoes and other foods high in starch - celiac disease - participants who are currently taking containing glucosamine sulphate or have taken products containing glucosamine sulphate in the last 8 weeks - cancer sufferers - failure to provide written consent - Diabetes Mellitus

Outcome results